Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
Status:
Terminated
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase III Study is to demonstrate the efficacy of at least one dose of
CHF 6532 on moderate and severe asthma exacerbations rate compared to placebo.